Fig. 7. Gpr35-mediated susceptibility to C. rodentium is rescued by pan-caspase inhibitor treatment.

C. rodentium CFU/g of (a) feces, (b) MLN and liver from Gpr35^f/fVil⁺ (n = 4) and Gpr35^wt co-housed littermates (n = 4) either treated with zVAD-FMK or untreated. c Representative AB/PAS staining of proximal colon sections obtained from Gpr35^f/fVil⁺ and Gpr35^wt co-housed littermates either treated with zVAD-FMK or untreated. Scale bars, 50 μm. d Cell count of goblet cells in (c) performed blindly by two different investigators in at least 30 crypts. e Representative images of proximal colon sections obtained from Gpr35^f/fVil⁺ and Gpr35^wt co-housed littermates either treated with zVAD-FMK or untreated and stained for Muc2 protein via immunohistochemistry. Scale bars, 50 μm. f mRNA expression levels of Muc2 measured by qRT-PCR in proximal colon samples obtained from Gpr35^f/fVil⁺ and Gpr35^wt co-housed littermates either treated with zVAD-FMK or untreated. Each dot represents one animal with medians. Data are represented as mean ± SEM *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 by two-way ANOVA with Tukey’s multiple comparisons test in (a) or Mann–Whitney in (b), (d) and (f).